Online inquiry

IVTScrip™ mRNA-Anti-LRRC15, PR-1498487(Cap 1, 2-Thio-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ13368MR)

This product GTTS-WQ13368MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 1 & 2-Thio-UTP. It ecodes the monoclonal antibody that targets LRRC15 gene. The antibody can be applied in Solid tumors research.
Specifications
Product type mRNA
Modified bases 2-Thio-UTP
5' Cap Cap 1
Species Chimeric; Humanized
RefSeq NM_001135057.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 131578
UniProt ID Q8TF66
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-LRRC15, PR-1498487(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) (GTTS-WQ13368MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ3908MR IVTScrip™ mRNA-Anti-CD274, BCD-135(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA BCD-135
GTTS-WQ12116MR IVTScrip™ mRNA-Anti-FOLR1, MORAb-003(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA MORAb-003
GTTS-WQ4978MR IVTScrip™ mRNA-Anti-GP, c2G4-N(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA c2G4-N
GTTS-WQ7455MR IVTScrip™ mRNA-Anti-TNFRSF4, GBR-830(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA GBR-830
GTTS-WQ7821MR IVTScrip™ mRNA-Anti-GLP1R, GSK 716155(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA GSK 716155
GTTS-WQ10429MR IVTScrip™ mRNA-Anti-MSTN, LY-2495655(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA LY-2495655
GTTS-WQ8793MR IVTScrip™ mRNA-Anti-PCSK9, IBI-306(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA IBI-306
GTTS-WQ10181MR IVTScrip™ mRNA-Anti-SELP, LC1004-002(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA LC1004-002
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW